or Try an Advanced Search...

    ETF Components for MNTL - Tema Neuroscience and Mental Health ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    VRTX D -1.02 7.90
    LLY F -1.30 5.40
    REGN F 0.64 5.20
    ALNY C 2.75 4.96
    ARGX A 1.58 4.21
    TEVA A 0.05 4.01
    CRNX B 1.30 3.86
    NBIX C 1.61 3.76
    BIIB F -0.12 3.48
    SYK A 3.05 3.25
    MDT B 0.92 3.04
    IONS F 0.96 2.47
    DNLI C 4.20 2.42
    ITCI A 2.11 2.16
    XENE C 1.41 2.16
    SRPT D -2.15 2.14
    RNA C -0.92 2.08
    CPRX A 0.41 2.06
    DAWN A -0.48 1.92
    NTLA F 4.15 1.87
    AXSM C -0.21 1.82
    JAZZ D 0.38 1.58
    IMVT F 0.44 1.49
    PEN A 1.94 1.41
    ALKS F 3.00 1.40
    DXCM C -0.18 1.32
    DYN F -0.42 1.30
    ACAD F 1.51 1.28
    OPCH F 4.64 1.27
    SRRK B -0.07 1.15
    PTCT B 1.38 1.13
    ACHC F -1.57 1.12
    PRTA F -2.06 0.99
    VYGR C 2.49 0.82
    ALEC D 2.03 0.57
    ARVN C 1.78 0.47
    QTRX C 1.63 0.46

    Represented by ETF Holdings

    Keywords: Biopharmaceutical Medicine Biotechnology Cancer Pain Alzheimer's Disease S&P 500 Biology Cholesterol Disease Life Sciences Parkinson's Disease Schizophrenia Amyloid Clinical Development Diabetes Disorders Genetics Neurological Disorders Chronic Pain
    Industries: Biotechnology Medical Devices Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic Medical Care Diagnostics & Research

    Recent News for Tema Neuroscience and Mental Health ETF & its Holdings

    Date Stock Title
    Nov 2 ITCI Here's What Analysts Are Forecasting For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) After Its Third-Quarter Results
    Nov 1 MDT Medtronic (MDT) Outperforms Broader Market: What You Need to Know
    Nov 1 LLY Lilly to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium
    Nov 1 MDT CMS grants Transitional Pass-Through Payment for Medtronic Symplicity Spyral™ renal denervation catheter
    Nov 1 LLY Market Volatility Soars Ahead Of Elections, Tech Earnings Mixed, Strikes And Hurricanes Knock Employment Down: This Week In The Markets
    Nov 1 TEVA Teva long-acting olanzapine shows improvements in schizophrenia patients
    Nov 1 LLY Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
    Nov 1 TEVA Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
    Nov 1 LLY Pharma Stock Roundup: MRK, PFE, ABBV, NVS, LLY's Q3 Earnings in Focus
    Nov 1 TEVA Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well ...
    Nov 1 DXCM DexCom (DXCM) Fell Due to an Uncharacteristic Earnings Miss
    Nov 1 VRTX Stocks to watch: Berkshire Hathaway, Super Micro, Novo Nordisk, Vistry and M&S
    Nov 1 LLY Stocks to watch next week: Berkshire Hathaway, Super Micro, Novo Nordisk, Vistry and M&S
    Nov 1 ACHC Here’s Why Acadia Healthcare Company (ACHC) Declined in Q3
    Nov 1 ARGX argenx downgraded at Baird as shares get pricey
    Nov 1 LLY Hims & Hers Health Faces Pressure Ahead of Earnings Amid Eli Lilly's GLP-1 News
    Nov 1 DAWN We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Easily Afford To Drive Business Growth
    Nov 1 ARVN Arvinas Third Quarter 2024 Earnings: Beats Expectations
    Nov 1 ALNY Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down
    Nov 1 OPCH Option Care Health Third Quarter 2024 Earnings: Beats Expectations
    Under normal circumstances, the Tema Neuroscience and Mental Health ETF seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in neuroscience and mental health companies. A company is generally considered to be a neuroscience or mental health company that derives at least 50% of revenues from neuroscience or neurology-related diseases, or mental health. The fund is non-diversified.
    Neuroscience Neurophysiology Neurology Nervous System
    Back to the Main MNTL Page...